Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04788745
Other study ID # MetFlex
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 29, 2021
Est. completion date May 24, 2023

Study information

Verified date November 2022
Source The University of Queensland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).


Description:

The study will consist of a 4-week lead-in period to obtain a stable baseline measurement of clinical markers of disease and oxidative stress. After the lead-in phase, participants will receive trimetazidine for 12 weeks. Participants will visit the clinic at 6-week intervals, during which we will obtain a blood sample to measure the pharmacodynamic response. We will also collect information regarding the rate of disease progression (i.e. ALSFRS-R and SVC). At weeks 3 and 9 of treatment, participants will conduct a teleconference visit, during which we will collect data on ALSFRS-R. Adverse events will be collected and recorded throughout the entire trial duration. At the end of the on-treatment period, a close-out visit will occur after four weeks. The total study period per participant will be 20 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date May 24, 2023
Est. primary completion date May 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age between 18 and 75 years - Signed informed consent prior to the initiation of any study-specific procedures - Familial or sporadic ALS/MND, defined as clinically possible, probable, or definite as per the El Escorial criteria - Relative TRICALS risk score between -6.0 to -2.0 (75% of patients with ALS/MND) - Metabolic index =110%, at the screening visit. - The use of riluzole will be permitted during the study. Individuals taking riluzole must be on a stable dose for at least 30 days prior to the baseline visit, or stopped taking riluzole at least 30 days prior to the baseline visit. - Ability to swallow tablets - Able to lie with torso elevated at a 35° angle for 30 minutes without respiratory support - Able to give informed consent (as judged by the investigator) and able to comply with all study visits and all study procedures - Females must not be able to become pregnant (e.g. post-menopausal, surgically sterile or using highly effective birth control methods) for the duration of the study. Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly, e.g. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: - oral - intravaginal - transdermal - Progestogen-only hormonal contraception associated with inhibition of ovulation: - oral - injectable - implantable - intrauterine device (IUD) - intrauterine hormone-releasing system ( IUS) - vasectomised partner - Females of child-bearing potential must have a negative serum pregnancy test at screening and baseline and be non-lactating Exclusion Criteria: - Unable to provide informed consent - History of, or current diagnosis of diabetes or medical condition that impacts whole body energy expenditure (e.g. Hashimoto's, heart disease) - Parkinson's disease or parkinsonism, tremor, restless-leg syndrome - Safety Laboratory Criteria at screening related to significant kidney disease: - Creatinine clearance < 50 mL / min (Cockcroft-Gault) based on Cystatin C - Tracheostomy or non-invasive ventilation (NIV) use > 22 hours per day - Inability to swallow tablets - Contraindication therapy: - Allergy for one of the product's active pharmaceutical ingredients (APIs) or excipients. - Antihypertensive treatment [Trimetazidine may cause hypotension] - Evidence of malignant disease - Significant neuromuscular disease other than ALS/MND - Ongoing disease that may cause neuropathy - Pregnancy or breastfeeding - Females actively seeking to become pregnant who are not using an adequate form of contraceptive as detailed in the Inclusion criteria. - Deprivation of freedom by administrative or court order

Study Design


Intervention

Drug:
Trimetazidine Dihydrochloride
Oral tablet, twice-daily

Locations

Country Name City State
Australia Royal Brisbane & Women's Hospital Brisbane Queensland
Netherlands University Medical Centre Utrecht Utrecht
United Kingdom King's College London London

Sponsors (5)

Lead Sponsor Collaborator
The University of Queensland FightMND, Julius Clinical, King's College London, UMC Utrecht

Countries where clinical trial is conducted

Australia,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events; Safety and Tolerability The occurrence of adverse events, as assessed by Common Terminology Criteria for AEs Version 5, during the 12-week on-treatment period and 4-week wash-out period (16 weeks total). 16 weeks
Primary Level of expression of oxidative stress markers in the plasma and/or serum of trial participants Expression of oxidative stress markers (malondialdehyde, 8-hydroxy-2'-deoxyguanosine, interleukin-6; assessed by liquid chromatography-mass spectrometry/mass-spectrometry or multiplexing) in the plasma and/or serum of trial participants throughout the treatment period (12-week) and at the end of the wash-out period (4 weeks) 16 weeks
Secondary Level of expression of oxidative stress markers in the plasma and/or serum of trial participants to inform future clinical trials in ALS/MND Assessment of the expression of oxidative stress markers (malondialdehyde, 8-hydroxy-2'-deoxyguanosine, interleukin-6; assessed by liquid chromatography-mass spectrometry/mass-spectrometry or multiplexing) in the plasma and/or serum of trial participants throughout the treatment period (12-week) and at the end of the wash-out period (4 weeks) to determine suitability for incorporation into future trial design 16 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04998305 - TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps Phase 1/Phase 2
Recruiting NCT05951556 - Telehealth Implementation of Brain-Computer Interface N/A
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04816227 - Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Active, not recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation Phase 1/Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT04220190 - RAPA-501 Therapy for ALS Phase 2/Phase 3
Not yet recruiting NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Phase 2
Not yet recruiting NCT06450691 - Modeling Amyotrophic Lateral Sclerosis With Fibroblasts N/A
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A